Arrowhead Pharmaceuticals Has Dosed The First Subjects In A Phase 1/2A Trial Of ARO-CFB, The Company's Investigational RNA Interference Therapeutic, In Up To 66 Healthy Volunteers And Patients With Complement Mediated Kidney Disease
Arrowhead Pharmaceuticals Has Dosed The First Subjects In A Phase 1/2A Trial Of ARO-CFB, The Company's Investigational RNA Interference Therapeutic, In Up To 66 Healthy Volunteers And Patients With Complement Mediated Kidney Disease
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.